Belatacept

Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,^[1] which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant^[2] survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.^{[medical citation needed]}

Belatacept

Clinical data
Trade names	Nulojix
AHFS/Drugs.com	Monograph
MedlinePlus	a606016
License data	EU EMA: by INN US DailyMed: Belatacept US FDA: Belatacept
Pregnancy category	AU: C
Routes of administration	Intravenous
ATC code	L04AA28 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only EU: Rx-only
Identifiers
CAS Number	706808-37-9 Y
DrugBank	DB06681 Y
ChemSpider	None
UNII	E3B2GI648A
KEGG	D03222
NY (what is this?)  (verify)

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.^[3]